Document is current

Article History

Received: 16 August 2021

Accepted: 11 October 2021

First Online: 6 December 2021

Declarations

:

: Due to the nature of the study (narrative review), there is no need for approval by an Ethics committee. No subjects or patients were included specifically for the purpose of this review.

: Not applicable.

: JPZ received speakers’ honoraria from Desitin Arzneimittel, GW Pharmaceuticals companies, and Eisai. FCS reports speakers’ honoraria and travel cost or study reimbursements from Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Medtronics, UCB Pharma, and Zogenix. FR reports personal fees and grants from Arvelle Therapeutics, Eisai GmbH, GSK, GW Pharmaceuticals companies, UCB Pharma, and MedilearnIndia. KK reports no conflicts of interest. ASei reports no conflicts of interest. AStr reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Marinus Pharma, UCB, UNEEG medical, and Zogenix. HS received lecture honoraria and reimbursements for travel costs from Eisai and Desitin and advisory fees from Novartis. The authors did not perform any experiments on humans or animals for the purposes of this paper. The studies reported here were performed according to the guidelines reported therein.